We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
According to a peer-reviewed analysis by MSF medicines used in the treatment of hepatitis c and cancer showed companies do not need SPCs to recoup R&D investments.